Bridge City Capital, LLC PCRX Pacira Biosciences

Ownership history in Bridge City Capital, LLC  ·  9 quarters on record

AI Ownership Summary

Bridge City Capital, LLC reported Pacira Biosciences (PCRX) in 9 quarterly 13F filings from 2024 Q1 through 2026 Q1. Peak portfolio weight reached 2.52% in 2026 Q1. The latest visible filing shows PCRX at 2.52% of the fund.

This page tracks quarterly shares, estimated market value, portfolio weight, filing dates, and disclosure-aligned stock prices directly from SEC EDGAR 13F filings.

What this PCRX ownership page tells you

This page is designed to answer the real investor question behind a 13F filing: how meaningful was Bridge City Capital, LLC's position in Pacira Biosciences, and how did that conviction change over time? You can read the holding window, peak weight, latest reported size, disclosure timing, and quarter-by-quarter changes without piecing the story together from raw SEC rows.

Freshest filing
Latest Reported Filing
2026 Q1

PCRX was reported at 2.52% of portfolio in the most recent visible filing.

High-water mark
Peak Conviction
2.52% in 2026 Q1

Peak weight helps separate a token disclosure from a real conviction holding the fund genuinely cared about.

Time in book
Holding Window
2024 Q1 to 2026 Q1

Longer holding windows often tell a very different story from short-lived tactical trades or one-quarter experiments.

Decision context
Why It Matters
Position size beats headlines

Knowing that a fund owned a stock is useful. Knowing whether it was a 0.20% placeholder or a true high-conviction position is where the signal actually starts.

How Bridge City Capital, LLC held PCRX — position size vs. price
% of Fund (quarterly)    PCRX price (quarter-end, indexed to 100)    SPY (indexed to 100)    QQQ (indexed to 100)
📋 Quarterly Holdings History 9 quarters  
Quarter Action Sold % After 3M Timing Shares Change Chg % % of Fund Mkt Value Filed Price (Filed)
2026 Q1 ADDED 402,765 +117,272 +41.1% 2.52% $9.1M 2026-05-13 $23.04
2025 Q4 REDUCED 8.3% -12.7% 285,493 -25,951 -8.3% 2.17% $7.4M 2026-02-13 $21.77
2025 Q3 ADDED 311,444 +141,771 +83.6% 2.14% $8.0M 2025-11-12 $23.86
2025 Q2 REDUCED 169,673 -2,473 -1.4% 1.14% $4.1M 2025-08-13 $25.04
2025 Q1 REDUCED 24.9% -3.8% 172,146 -57,050 -24.9% 1.28% $4.3M 2025-04-14 $24.97
2024 Q4 REDUCED 229,196 -2,019 -0.9% 1.15% $4.3M 2025-02-11 $27.25
2024 Q3 ADDED 231,215 +146,359 +172.5% 0.96% $3.5M 2024-11-14 $16.37
2024 Q2 ADDED 84,856 +22,912 +37.0% 0.82% $2.4M 2024-08-13 $12.40
2024 Q1 INITIATED 61,944 0.66% $1.8M 2024-04-12 $26.83

FAQ About Bridge City Capital, LLC and PCRX

These are the practical questions this page is built to answer before you even open the full history table.

How long has Bridge City Capital, LLC reported owning PCRX?

Bridge City Capital, LLC reported PCRX across 9 quarterly 13F filings, from 2024 Q1 through 2026 Q1.

What was the largest reported PCRX position in Bridge City Capital, LLC's portfolio?

The largest reported portfolio weight for PCRX was 2.52% in 2026 Q1.

What is the latest reported PCRX position on this page?

The most recent filing on this page is 2026 Q1, when Bridge City Capital, LLC reported 402,765 shares, equal to 2.52% of portfolio, with an estimated market value of $9.1M.

What does the chart on this PCRX ownership page compare?

The chart compares Bridge City Capital, LLC's quarterly PCRX portfolio weight with the stock's indexed share price, so you can see whether the fund was building, trimming, or holding the position as price moved.

How well did Bridge City Capital, LLC time their PCRX position?

Based on 13F filing dates vs. subsequent PCRX price moves, Bridge City Capital, LLC correctly timed 4 out of 8 reported position changes (50%). The annualised alpha on PCRX relative to SPY over the holding period was -25.4%.

← Back to Bridge City Capital, LLC Holdings